Outputs (1)

Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial (2013)
Journal Article
RD Johnston, S., Kilburn, L. S., Ellis, P., Dodwell, D., Cameron, D., Hayward, L., …investigators, S. (2013). Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. Lancet Oncology, 14(10), 989-998. https://doi.org/10.1016/S1470-2045%2813%2970322-X